рекомендации при множественной миеломе. Удк национальные клинические рекомендации по диагностике и лечению множественной миеломы
 Скачать 0.65 Mb.
|
|
Blood. 2011; 117(18): 4701–5. doi: 10.1182/blood-2010-10-299529. • Dimopoulos M.A., Palumbo A., Attal M., Beksaç M., Davies F.E., Delforge M., et al.; European Myeloma Network. Optimization the use of lenalidomide in relapse or refractory multiple myeloma: consensus statement. Leukemia. 2011; 25(5): 749–60. doi: 10.1038/leu.2011.3. • Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 2007; 357(21): 2123–32. • Durie B.G., Harousseau J.L., Miguel J.S., Bladé J., Barlogie B., Anderson K., et al.; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9): 1467–73. • Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma: Correlation of measure myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(9): 842–54. • Einsele H., Liebisch P., et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial). Blood. 2009; 114: abstr. 131. • Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer. 2013; 49(6): 1374–403. doi: 10.1016/j.ejca.2012.12.027. • Greipp P.R., San Miguel J.F., Durie B.G., Crowley J.J., Barlogie B., Bladé J., et al. International staging system for multiple myeloma. J. Clin. Oncol. 2005; 23(15): 3412–20. • Harousseau J.L., Dreyling M.; ESMO Guidelines Working Group. Multiple Myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21(Suppl. 5): v155–7. doi: 10.1093/annonc/mdq178. • Hoskin P.J., Yarnold J.R., Roos D.R., Bentzen S.; Second Workshop on Palliative Radiotherapy and Symptom Control. Radiotherapy for bone metastases. (Second Consensus Workshop in Palliative Radiotherapy and Symptom Control. London, 2000). Clin. Oncol. (R Coll Radiol). 2001; 13(2): 88–90. • Howlader N., Noone A.M., Krapcho M., Garshell J., Miller D., Altekruse S.F., et al.; eds. SEER Cancer Statistics Review, 1975– 2012. Bethesda: National Cancer Institute. http://seer.cancer.gov/ csr/1975_2012/, April 2015. • Hrusovsky I., Emmerich B., von Rohr A., Voegeli J., Taverna C., Olie R.A., et al. Bortezomib retreatment in relapsed multiple myeloma – results from a retrospective multicentre survey in Germany and Switzerland. Oncology. 2010; 79(3–4): 247–54. • International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of International Myeloma Working Group. Br. J. Haematol. 2003; 121(5): 749–57. • Jagannath S., Durie B.G., Wolf J.L., Camacho E.S., Irwin D., Lutzky J., et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for frontline treatment of multiple myeloma. Br. J. Haematol. 2009; 146(6): 619–26. doi: 10.1111/j.1365-2141.2009.07803.x. • Jagannath S., Richardson P.G., Barlogie B., Berenson J.R., Singhal S., Irwin D., et al.; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the tretment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006; 91(7): 929–34. • Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60(5): 277–300. doi: 10.3322/caac.20073. • Knop S., Gerecke C., Liebisch P., Topp M.S., Platzbecker U., Sezer O., et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group РЕКОМЕНДУЕМАЯ ЛИТЕРАТУРА Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В., Сте- панова Н.В., Мачюлайтене ЕР, Салогуб Г.Н. и др. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получающих бор- тезомиб (велкейд). Онкогематология. 2008; 3: 52–62. • Вотякова ОМ. Множественная миелома. В кн Переводчи- кова НИ, ред. Руководство по химиотерапии опухолевых заболеваний М Практическая медицина 2011: 362–72. • Вотякова ОМ, Османов Д.Ш., Демина Е.А., Фалалеева НА, Бялик ТЕ, Рябухина Ю.Е. и др. Использование вел- кейда при множественной миеломе. Терапевтический архив 2007; 7: 70–3. • Давыдов МИ, Аксель ЕМ. Статистика злокачественных новообразований России и странах СНГ 2007 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009; приложение 1): 1–156. • Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность. Москва МНИОИ им. ПА. Герцена; 2013. • Менделеева Л.П. Современное лечение множественной мие- ломы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2009; 1: 64–5. • Покровская ОС, Менделеева Л.П., Урнова Е.С., Гапонова Т.В., Гальцева ИВ, Кузьмина Л.А. и др. Влияние бортезо- миба на эффективность мобилизации гемопоэтических стволовых клеток крови у больных множественной миеломой. Терапевтический архив 2012; 7: 35–41. Остальные источники литературы см. в References R E F E R E N C E S • Alexanian R., Dimopoulos M.A., Delasale K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992; 80(4): 887–90. • Avet-Loiseau H., Leleu X., Roussel M., Moreau P., Guerin- Charbonnel C., Caillot D., et al. Bortezomib plus dexamethasone induction improves outcome in patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 2010; 28(30): 4630–4. doi: 10.1200/JCO.2010.28.3945. • Barlogie B., Attal M., Crowley J., van Rhee F., Szymonifka J., Moreau P., et al. Long-term follow-up of autotransplantation trails for multiple myeloma: update of protocols conducted by the intergroup francophone du myelome, southwest oncology group, and university of Arkansas for medical sciences. J. Clin. Oncol. 2010; 28(7): 1209–14. doi: 10.1200/JCO.2009.25.6081. • Bray F., Ren J.S., Masuyer E., Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer. 2013; 132(5): 1133–45. doi: 10.1002/ijc.27711. • Bringhen S., Larocca A., Rossi D., Cavalli M., Genuardi M., Ria R., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010; 116(23): 4745–53. doi: 10.1182/blood-2010-07-294983. • Dadacaridou M., Papanicolaou X., Maltesas D., Megalakaki C., Patos P., Panteli K., et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J. BUON. 2007; 12(1): 41–4. • Damaj G., Malard F., Hulin C. Efficacy of Bendamustine in relapsed/refractory myeloma patients: Results from the French compassionate use program. Haematologica. 2011; 96 (Suppl.1): abstr. 140. • Davies F.E., Wu P., Jenner M., Srikanth M., Saso R., Morgan G.J. The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica. 2007; 92(8): 1149–50. • Dimopolous M., Chen C., Spencer A., Niesvizky R., Attal M., Stadtmauer E.A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11): 2147–52. doi: 10.1038/leu.2009.147. 23 Hematology and Transfusiology. 2016; 61(1, Suppl. 2) therapy followihg single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 BMT-CTN 100104. Haematologica. 2011; 96(Suppl. 1): S23. • McCarthy P.L., Owzar K., Hofmeister C.C., Hurd D.D., Hassoun H., Richardson P.G., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2012; 366(19): 1770–81. doi: 10.1056/NEJMoa1114083. • Morgan G.J., Child J.A., Gregory W.M., Szubert A.J., Cocks K., Bell S.E., et al.; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcome from a randomized controlled trial. Lancet Oncol. 2011; 12(8): 743–52. doi: 10.1016/S1470- 2045(11)70157-7. • Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Grishunina M., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet Oncol. 2011; 12(5): 431–40. doi: 10.1016/S1470- 2045(11)70081-X. • Moreau P., San Miguel J., Ludwig H., Schouten H., Mohty M., Dimopoulos M., Dreyling M.; ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(Suppl. 6): vi133–7. doi: 10.1093/annonc/mdt297. • Munshi N.C., Anderson K.C., Bergsagel P.L., Shaughnessy J., Palumbo A., Durie B., et al.; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117(18): 4696–700. doi: 10.1182/blood-2010-10-300970. • NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM) Multiple Myeloma Version 2.2014. http://www. NCCN.org • Niesvizky R., Flinn I.W., Rifkin R.M., et al. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple Myeloma patients [abstract]. Blood. 2010; 116: Abstr. 619. • Orlowski R.Z., Nagler A., Sonneveld P., , Bladé J., Hajek R., Spencer A., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 2007; 25(25): 3892–901. • Palumbo A., Bringhen S., Rossi D., Cavalli M., Larocca A., Ria R., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 2010; 28(34): 5101–9. doi: 10.1200/JCO.2010.29.8216. • Palumbo A., Bringhen S., Zweegman S., et al. Secondary Malignancies in Elderly Myeloma Patients. Haematologica. 2011; 96(Suppl. 1): 24. • Palumbo A., Hajek R., Delforge M., Kropff M., Petrucci M.T., Catalano J., et al.; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 2012; 366(19): 1759–69. doi: 10.1056/ NEJMoa1112704. • Palumbo A., Magarotto V. Novel treatment paradigm for elderly patients with multiple myeloma. Am. J. Blood Res. 2011; 1(2): 190–204. • Petrucci M.T., Giraldo P., Corradini P., et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br. J. Haematol. 2013; 160(5): 649–59. doi: 10.1111/bjh.12198. • Pönisch W., Mitrou P.S., Merkle K., Herold M., Assmann M., Wilhelm G., et al.; East German Study Group of Hematology and Oncology (OSHO). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009; 113(18): 4137–43. doi: 10.1182/blood-2008-10-184135. • Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica. 2005; 90(9): 1287–8. • Knopf K.B., Duh M.S., Lafeuille M.H., Gravel J., Lefebvre P., Niculescu L., et al. Meta-analysis of the efficacy and safety of Bortezomib retreatment in patients with multiple myeloma (MM). Blood. 2012; 120(21): abstr. 1863. • Kropff M., Bisping G., Schuck E., Liebisch P., Lang N., Hentrich M., et al.; Deutsche Studiengruppe Multiples Myelom. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br. J. Haematol. 2007; 138(3): 330–7. • Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23(1): 3–9. doi: 10.1038/leu.2008.291. • Kyle R.A., Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 2004; 351(18): 1860–73. • Larocca A., Oliva S., Offinady M., et al. Subcutaneous velcade plus prednisone (VP) or plus cyclophosphamide (VCP) or plus melphalan (VMP) in frail, elderly, newly diagnosed multiple myeloma patients: a phase II community-based study. Haematologica. 2013; 98(Suppl. 1): 477 (Abstr. S1154). • Lenhard R.E., Oken M.M., Barnes J.M., Humphrey R.L., Glick J.H., Silverstein M.N. High-dose cyclophosphamide. An effective treatment for avanced refractory multiple myeloma. Cancer. 1984; 53(7): 1456–60. • Lentzsch S., O’Sullivan A., Kennedy R., et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of phase I/II open-label, dose escalation study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011; 118(21): 304. • Ludwig H., Avet-Loiseau H., Bladé J., Boccadoro M., Cavenagh J., Cavo M., et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist. 2012; 17(5): 592–606. doi: 10.1634/ theoncologist.2011-0391. • Ludwig H., Durie B.G., McCarthy P., Palumbo A., San Miguel J., Barlogie B., et al.; International Myeloma Working Group. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012; 119(13); 3003–15. doi: 10.1182/blood-2011-11-374249. • Ludwig H., Kasparu H., Griel R., et al. Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in relapsed/ refractory multiple myeloma shows significant activity and is well tolerated. Blood. 2012; 120: Abstr. 943. • Malpas J.S., Bergsagel D.E., Kyle R.A., Anderson C.A., eds. Myeloma: Biology and management. Oxford, New York, Tokyo: Oxford University Press; 1998. • Mateos M.V., Oriol A., Martínez-López J., Gutiérrez N., Teruel A.I., de Paz R., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010; 11(10): 934-41. doi: 10.1016/S1470- 2045(10)70187-X. • Mateos M.V., Richardson P.G., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J. Clin. Oncol. 2010; 28(13): 2259–66. doi: 10.1200/JCO.2009.26.0638. • Mateos M.V., San Miguel J.F. How should we treat newly diagnosed multiple myeloma patients? Hematology Am. Soc. Hematol. Educ. Program. 2013; 2013: 488–95. doi: 10.1182/ asheducation-2013.1.488. • McCarthy P.L., Owzar K., Anderson K.C., et al. Phase III intergroup study of Lenalidomide versus placebo maintenance Гематология и трансфузиология. 2016; 61(1, Приложение 2) M., et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open- label, phase III trial. Lancet Oncol. 2013; 14(11): 1055–66. doi: 10.1016/S1470-2045(13)70380-2 • Schey S.A., Morgan G.J., Ramasamy K., Hazel B., Ladon D., Corderoy S., et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br. J. Haematol. 2010; 150(3): 326–33. doi: 10.1111/j.1365-2141.2010.08250.x. • Sonneveld P., Jongen J.L. Dealing with neuropathy in plasma- cell dyscrasias. Hematology Am. Soc. Hematol. Educ. Program. 2010; 2010: 423–30. doi: 10.1182/asheducation-2010.1.423. • Sonneveld P., Schmidt-Wolf I., van der Holt B., Jarari L., Bertsch U., Salwender H., et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma. Blood. 2010; 116: abstr 40. https://ash.confex.com/ash/2010/webprogram/ Paper29306.html • Stadtmauer E.A., Weber D.M., Niesvizky R., Belch A., Prince M.H., San Miguel J.F., et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur. J. Haematol. 2009; 82(6): 426–32. doi: 10.1111/j.1600- 0609.2009.01257.x. • van de Donk N.W., Görgün G., Groen R.W., Jakubikova J., Mitsiades C.S., Hideshima T., et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag. Res. 2012; 4: 253–68. doi: 10.2147/CMAR.S27087. • Vickrey E., Allen S., Mehta J., Singnal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. |